Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Zolbetuximab, Durvalumab, and FLOT (5-FU, Leucovorin, Oxaliplatin, and Docetaxel) Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT07872722 is registered in ClinicalTrials.gov with National Cancer Center, Japan as lead sponsor.

NCT NCT07872722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07872722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Zolbetuximab, Durvalumab, and FLOT (5-FU, Leucovorin, Oxaliplatin, and Docetaxel) Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
National Cancer Center, Japan
Phase
Phase 2
Overall status
Recruiting
Start date
August 13, 2026
Completion date
March 31, 2030
Enrollment
29 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cldn18.2-positive gastric cancer, cldn18.2-positive gastroesophageal junction adenocarcinoma